A phase II neoadjuvant trial of sequential tri-weekly nanoparticle albumin-bound paclitaxel (Abraxane)/cyclophosphamide, with trastuzumab in HER2-positive patients, followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer - TRI-ABC FEC trial

The treatment outcomes and safety were evaluated in 54 patients who received at least 1 dose of chemotherapy. The overall pCR rate of 37% was achieved. The pCR rates according to each subtype were 8% in hormone receptor (HR)-positive HER2-negative breast cancer, 56% in HR-positive HER2-positive breast cancer, 63% in HR-negative HER2-positive breast cancer, and 62% in triple-negative breast cancer. Clinical response was observed in 49 patients (91%). The safety profile was acceptable.